
    
      A Phase III Randomised, Double blind, Placebo controlled, Parallel, Multicentre Study to
      Assess the Efficacy and Safety of continuing IRESSA 250 mg in addition to Chemotherapy versus
      Chemotherapy alone in Patients who have Epidermal Growth Factor Receptor (EGFR) Mutation
      Positive Locally advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and have
      progressed on First Line IRESSA.
    
  